Plain Language Summary What is the context? Herpes zoster, commonly known as shingles, is a painful rash resulting from the reactivation of the dormant virus causing chickenpox. Vaccines preventing shingles, such as Shingrix , were shown to be well tolerated and efficacious in healthy adults over 50 years of age from Europe, North and Latin America, Australia, and Asia (Taiwan, Hong Kong, Korea, Japan). However, data on real-world protective effect of Shingrix are limited in some regions where the vaccine is licensed for use, such as mainland China. What is new? We analyzed data from Chinese adults aged 50 years or older to determine the efficacy and safety of Shingrix . Around 6000 participants were divided in two equal groups to receive two doses of Shingrix or two doses of a placebo, given 2 months apart. We found that, during the study period, the vaccine was 100% efficacious in preventing shingles. We showed that the vaccine had an acceptable safety profile in this Chinese population. What is the impact? Shingrix is efficacious and well tolerated in Chinese adults over 50 years of age, as it is in similarly aged populations from other evaluated regions.
【저자키워드】 reactogenicity, Safety, vaccine efficacy, herpes zoster, adjuvanted recombinant zoster vaccine,